➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Johnson and Johnson
Harvard Business School
Merck
Colorcon

Last Updated: June 17, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for AIN457


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug AIN457?

AIN457 is an investigational drug.

There have been 55 clinical trials for AIN457. The most recent clinical trial was a Phase 3 trial, which was initiated on January 16th 2018.

The most common disease conditions in clinical trials are Arthritis, Psoriasis, and Arthritis, Psoriatic. The leading clinical trial sponsors are Novartis Pharmaceuticals, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), and Novartis.

There are three US patents protecting this investigational drug and five international patents.

Recent Clinical Trials for AIN457
TitleSponsorPhase
Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.Novartis PharmaceuticalsPhase 3
Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial SpondyloarthritisNovartis PharmaceuticalsPhase 3
A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)Novartis PharmaceuticalsPhase 3

See all AIN457 clinical trials

Clinical Trial Summary for AIN457

Top disease conditions for AIN457
Top clinical trial sponsors for AIN457

See all AIN457 clinical trials

US Patents for AIN457

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AIN457   Get Started Free Methods of administering IgG1 antibodies and methods of suppressing angiogenesis University of Kentucky Research Foundation (Lexington, KY)   Get Started Free
AIN457   Get Started Free Substituted pyrimidinone-phenyl-pyrimidinyl compounds CONFLUENCE LIFE SCIENCES, INC. (St. Louis, MO)   Get Started Free
AIN457   Get Started Free Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients Corning Incorporated (Corning, NY)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AIN457

Drugname Country Document Number Estimated Expiration Related US Patent
AIN457 Canada CA2907548 2033-03-13   Get Started Free
AIN457 European Patent Office EP2968556 2033-03-13   Get Started Free
AIN457 World Intellectual Property Organization (WIPO) WO2014160336 2033-03-13   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
AstraZeneca
Boehringer Ingelheim
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.